Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Vor Bio logo — Vor Bio's vision is to cure blood cancers through cell and g...

Vor Bio

Vor Bio's vision is to cure blood cancers through cell and genome engineering.

Founded 2016 United States Cambridge, United States 110 employees Post-IPO Equity Total: $267.80M Biotechnology, Health Care +1

General Information

Company Name Vor Bio
Founded Year 2016
Location United States Cambridge, United States
Employees 110
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Vor Bio. To contact Vor Bio, visit vorbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vor Bio compare?

A PDF of Vor Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vor Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vor Bio

Vor Bio is a biotechnology startup founded in 2016 with a vision to cure blood cancers through cell and genome engineering. The company's slogan, "Vor Bio's vision is to cure blood cancers through cell and genome engineering," encapsulates its ambitious goal. Vor Bio is a clinical-stage company based in the United States that focuses on changing the standard of care for patients with blood cancers. Their approach involves engineering hematopoietic stem cells to enable targeted therapies post-transplant. In December 2022, Vor Bio secured a significant $115.80M in Post-IPO Equity investment from RA Capital Management. This infusion of capital not only demonstrates investor confidence in Vor Bio's mission and technology but also provides the financial resources necessary for the company to advance its clinical programs and continue its research and development efforts. This investment serves as a testament to the potential impact of Vor Bio's innovative approach in tackling blood cancers. Overall, Vor Bio's unique focus on leveraging cell and genome engineering to address blood cancers, combined with the substantial investment it has secured, positions the company as a compelling player in the biotechnology and healthcare industries. Furthermore, the backing of notable investors like RA Capital Management indicates external validation of the company's potential to make a significant mark in the field of oncology.

Business keywords: biopharma, genome engineering, cell therapy, cancer treatment, immuno-oncology, clinical-stage company, hematopoietic stem cells, targeted therapies, selective targeting, therapy development, immunotherapies, bi-specific antibodies, CAR-T therapy, toxicity management, cancer research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $115.80M 1
RA Capital Management
RA Capital Management
07 Dec 2022
Series B $110.00M 8
RA Capital Management 5AM Ventures Alexandria Venture Investments
RA Capital Management, 5AM Ventures +6
07 Jul 2020
Series A $42.00M 1
OUP (Osage University Partners)
14 Feb 2019

Vor Bio Alternatives & Competitors

View All Alternatives
Vor Bio vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Vor Bio vs
Cabaletta Bio
Cabaletta Bio United States

Engineered T cell therapies designed for the treatment of patients with autoimmune diseases

IPO
191 employees
Biotechnology, Pharmaceutical
Vor Bio vs
Orca Bio
Orca Bio United States

Transforming allogeneic cell therapy for patients with cancer and autoimmune diseases.

Series D
327 employees
Health Care, Pharmaceutical
View all alternatives

FAQ About Vor Bio

Vor Bio's vision is to cure blood cancers through cell and genome engineering.
Vor Bio was founded in 2016.
Vor Bio is headquartered in Cambridge, United States.
Vor Bio operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharma, genome engineering, cell therapy and cancer treatment.
Vor Bio has approximately 110 employees.
Vor Bio has completed 3 funding rounds, raising a total of $267.80M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Vor Bio include Adicet Bio, Inc, Cabaletta Bio, Orca Bio, MimiVax, Inc., Tango Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vor Bio and Adicet Bio, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vor Bio, https://bouncewatch.com/company/vor-bio, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes